Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc. successfully held its Annual General Meeting on June 28, 2024, with all proposed resolutions passed unanimously, signaling strong support from the shareholders. As a leader in light-activated antimicrobial therapies, the company continues to advance its photodisinfection technology with multiple products in development and a nasal photodisinfection system that has received international approvals and is undergoing clinical trials in the US.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
